Soligenix Inc. will collaborate with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation to recruit patients for its phase III clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.
MAURIZIO D’INCALCI will receive an award in recognition of his scientific career at the Special Conference on Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic, organized by the European Association of Cancer Research, the American Association of Cancer Research and the Italian Cancer Society and that will be held in Florence,... […]
Cigna Corp. issued a positive coverage decision for VeriStrat serum proteomic testing developed by Biodesix Inc. Cigna published its position to extend coverage for the VeriStrat blood-based test, stating the test is “…medically necessary for an individual with advanced non-small cell lung cancer (NSCLC)…”
Five members are rotating off THE NCI BOARD OF SCIENTIFIC ADVISORS. They are: Todd Golub, (chair), chief scientific officer at the Broad Institute of Massachusetts Institute of Technology and Harvard University. Curt Civin, director of the Center for Stem Cell Biology and a regenerative medicine professor of pediatrics and physiology associate dean for research at... […]
Amgen and Roche announced they will collaborate on a phase Ib study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.
Advaxis Inc. submitted a Special Protocol Assessment request to the FDA to initiate detailed design discussions for a phase III clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer.
Thousands of U.S. patients may be undergoing unnecessary lung biopsies and surgeries annually due to overtreatment of benign lung nodules, according to a study published in the journal CHEST.
A $20.65 billion agriculture appropriations bill, which cleared a House subcommittee June 18, seeks to limit FDA's ability to review electronic cigarettes, cigars and other tobacco products already on the market.
Oregon Health & Science University met the challenge posed by Nike co-founder Phil Knight and his wife Penny by raising $500 million in less than two years, earning the Knights' matching gift and setting a $1 billion fundraising record. The announcement was made June 25.
The American Society of Clinical Oncology earlier this week published a proposed framework for assessing the value of new cancer treatments.
